Key result
Enoximone improved hemodynamic performance in refractory postcardiotomy cardiogenic shock, increasing cardiac index from 1.56 to 2.72 l/min/m2.
Why the study?
Does enoximone improve hemodynamic parameters in patients with refractory postcardiotomy cardiogenic shock?
Observational (n=13)
Does enoximone improve hemodynamic parameters in patients with refractory postcardiotomy cardiogenic shock?
Enoximone significantly improves hemodynamic performance in patients with severe postcardiotomy cardiogenic shock refractory to conventional therapies.
Answers are grounded in this paper and cite their sources.
Should not yet change practice in refractory postcardiotomy cardiogenic shock; hypothesis-generating pending controlled trials.
The efficacy of the phosphodiesterase inhibitor enoximone for reversal of severe postcardiotomy low cardiac output syndrome was investigated in 13 cases of cardiogenic shock refractory to conventional treatment consisting of beta-adrenergic agonists (n = 13) combined with vasodilators (n = 7), and intra-aortic balloon counterpulsation (n = 5). Following a bolus of 1 mg/kg enoximone, cardiac and stroke volume indices increased from 1.56 +/- 0.27 l/min/m2 and 16.3 +/- 3.3 ml/m2, respectively, to 2.72 +/- 0.67 and 27.8 +/- 7.1 (both p < 0.001). Mean arterial pressure fell, from 77 +/- 11 to 68 +/- 9 mmHg (p < 0.05), as did atrial filling pressures (LAP and RAP), LAP from 21.3 +/- 5.5 to 15.9 +/- 2.9 and RAP from 16.6 +/- 2.3 to 13.7 +/- 2.1 mmHg (both p < 0.01). The heart rate rose by only 5%. Enoximone therapy was maintained by a continuous infusion (5-7.5 micrograms/kg/min) for 40.6 +/- 8.6 hours (range 14-92). All hemodynamic parameters remained stable throughout treatment. Six patients died of sepsis and/or multiorgan failure but seven were discharged from hospital. Enoximone thus improved hemodynamic performance significantly in cardiogenic shock after open-heart surgery. It also has proved valuable in cardiac failure when conventional therapy was unsuccessful.
No takes yet. Share an insight, caveat, or question.
Iversen et al. (1992) conducted an observational in Postcardiotomy cardiogenic shock (n=13). Enoximone vs. Baseline (pre-treatment) was evaluated on Cardiac index (p=<0.001). Enoximone improved hemodynamic performance in refractory postcardiotomy cardiogenic shock, increasing cardiac index from 1.56 to 2.72 l/min/m2.
Synapse has enriched 10 related papers. Consider them for comparative context: